Dr. Thomas Helleday of Karolinska Institutet and his colleagues have identified a new way of treating cancer by inhibiting the enzyme MTH1, which cancer cells require for survival. Credit: Ulf Sirborn
A team of researchers from five Swedish universities, led by Karolinska Institutet and the Science for Life Laboratory, have identified a new way of treating cancer. The concept is presented in the journal Nature and is based on inhibiting a specific enzyme called MTH1, which cancer cells, unlike normal cells, require for survival. Without this enzyme, oxidized nucleotides are incorporated into DNA, resulting in lethal DNA double-strand breaks in cancer cells.
"To accelerate the development of this treatment principle and to proceed with clinical trials in patients as quickly as possible, we are working with an open innovation model. Even before publication, we have sent out MTH1 inhibitors to a range of research groups worldwide", says Thomas Helleday, holder of the Söderberg Professorship at Karolinska Institutet, who heads the study.
In recent decades, the development of new anticancer agents has focused on targeting specific genetic defects in cancer cells. These are often effective initially, but are troubled with rapid resistance emerging. In the current study, the researchers present a general enzymatic activity that all cancers tested rely on and that seems to be independent of the genetic changes found in specific cancers. The research team shows that all the investigated cancer tumours need the MTH1 enzyme to survive. In this way, cancer cells differ from normal cells, which do not need this enzyme.
"The concept is built on that cancer cells have an altered metabolism, resulting in oxidation of nucleotide building blocks", says Thomas Helleday."MTH1 sanitises the oxidized building blocks, preventing the oxidative stress to be incorporated into DNA and becoming DNA damage. This allows replication in cancer cells so they can divide and multiply. With an MTH1 inhibitor, the enzyme is blocked and damaged nucleotides enter DNA, causing damage and kill cancer cells. Normal cells do not need MTH1 as they have regulated metabolism preventing damage of nucleotide building blocks. Finding a general enzymatic activity required only for cancer cells to survive opens up a whole new way of treating cancer,"
To take the treatment concept to towards a clinical application, the scientists have taken a multidisciplinary collaboration strategy with researchers from five Swedish universities. They have produced a potent MTH1 inhibitor that selectively kills cancer cells in the tumours that have been surgically removed from skin cancer patients. Dr Roger Olofsson Bagge is a surgeon at Sahlgrenska University Hospital, and also affiliated with the Sahlgrenska Academy at the University of Gothenburg:
"When we saw that the tumour from one of my melanoma patients who has developed resistance to all the current treatment actually responded very well to the treatment, we were extremely happy. It's rare that you get to experience and witness such a breakthrough," he says.
However, a lot of work remains to be done before it is time for clinical trials, which is likely to take at least one or two years, according to Thomas Helleday. In another article published in the same issue of Nature parts of the Swedish research team, together with collaborators in Austria and the UK present results showing that even previously identified substances that kill cancer cells work by inhibiting the MTH1 enzyme, something which has not been realised until now.
"That existing anticancer agents hit the MTH1 shows that the concept really works. Now that we understand the mechanism, we can develop very selective inhibitors", says Thomas Helleday.
Explore further: Acidic tumour pH inhibits drug effect
More information: 'MTH1 inhibition kills cancer by preventing sanitation of the dNTP pool', Helge Gad, Tobias Koolmeister, Ann-Sofie Jemth et al., Nature, online 2 April 2014, DOI: 10.1038/nature13181
'Stereospecific targeting of MTH1 by (S)-crizotinib as anticancer strategy', Kilian V. M. Huber, Eidarus Salah, Branka Radic et al., Nature, online 2 April 2014, DOI: 10.1038/nature13194
Medical Xpress on facebook
Related Stories
Acidic tumour pH inhibits drug effect
Feb 11, 2014
Low pH in tumours counteracts the desired effect of the drug chloroquine, according to a new study from Karolinska Institutet in Sweden. The results, which are published in the journal Autophagy, might explain ...
Novel cancer cell DNA damage repair mechanism unveils
Dec 10, 2013
Research with a Finnish background facilitates the development of more effective cancer medication
New drug candidate starves dormant cancer cells
Feb 18, 2014
In a study published in Nature Communications, researchers at Karolinska Institutet and Uppsala University in Sweden present a new drug candidate, which selectively kills dormant cells within a cancer tumour through starva ...
Alcohol-breakdown molecule may play a role in breast cancer development
Feb 11, 2014
(Medical Xpress)—New research looking at the biological process involved in breast cancer development has strengthened the argument for a potential link between alcohol consumption and the disease.
Cancer vaccine a step closer as natural killer cells are rightly activated
Mar 25, 2014
Vaccines work. Their widespread use has saved millions of lives. With an ageing population that is increasingly becoming a victim to cancer, a vaccine to treat it would do wonders. In a study published in ...
Recommended for you
Pathological complete response predictor of favorable breast cancer outcome
1 hour ago
Results of EORTC trial 10994 appearing in the Annals of Oncology show that pathological complete response after neoadjuvant chemotherapy is an independent predictive factor of favorable clinical outcomes in all ...
An easier, safer, and more accurate treatment for pancreatic cancer
3 hours ago
Using CT scans with contrast enhancement, Dartmouth researchers measured treatment response to pancreatic cancer photodynamic therapy (PDT) according to a paper published in Physics in Medicine and Biology.
Green light for Phase II clinical trial using interstitial photodynamic therapy
4 hours ago
Roswell Park Cancer Institute (RPCI) has received U.S. Food and Drug Administration (FDA) approval to enroll patients in a phase II clinical trial that will use a unique and highly precise method of delivering interstitial ...
Three DNA methylation markers ID recurrence in bladder cancer
5 hours ago
(HealthDay)—For patients with noninvasive urothelial carcinoma, three DNA methylation markers are able to accurately predict tumor recurrence, according to a study published in the April 1 issue of Clinical Ca ...
World-first clinical trial launches for advanced bowel cancer
5 hours ago
Patients with advanced bowel cancer are set to benefit from the launch of a revolutionary new clinical trial targeting treatments to their specific cancer type as well as rapidly adapting to include new drugs ...
Cell metabolism discovery could lead to treatments for cancer, common cold
6 hours ago
(Medical Xpress)—Scientists at UCLA's Jonsson Comprehensive Cancer Center have published the first study explaining in detail how viruses reprogram the metabolism of the cells they invade to promote continued viral growth ...
User comments
© Medical Xpress 2011-2014, Science X network
Dr. Thomas Helleday of Karolinska Institutet and his colleagues have identified a new way of treating cancer by inhibiting the enzyme MTH1, which cancer cells require for survival. Credit: Ulf Sirborn
A team of researchers from five Swedish universities, led by Karolinska Institutet and the Science for Life Laboratory, have identified a new way of treating cancer. The concept is presented in the journal Nature and is based on inhibiting a specific enzyme called MTH1, which cancer cells, unlike normal cells, require for survival. Without this enzyme, oxidized nucleotides are incorporated into DNA, resulting in lethal DNA double-strand breaks in cancer cells.
"To accelerate the development of this treatment principle and to proceed with clinical trials in patients as quickly as possible, we are working with an open innovation model. Even before publication, we have sent out MTH1 inhibitors to a range of research groups worldwide", says Thomas Helleday, holder of the Söderberg Professorship at Karolinska Institutet, who heads the study.
In recent decades, the development of new anticancer agents has focused on targeting specific genetic defects in cancer cells. These are often effective initially, but are troubled with rapid resistance emerging. In the current study, the researchers present a general enzymatic activity that all cancers tested rely on and that seems to be independent of the genetic changes found in specific cancers. The research team shows that all the investigated cancer tumours need the MTH1 enzyme to survive. In this way, cancer cells differ from normal cells, which do not need this enzyme.
"The concept is built on that cancer cells have an altered metabolism, resulting in oxidation of nucleotide building blocks", says Thomas Helleday."MTH1 sanitises the oxidized building blocks, preventing the oxidative stress to be incorporated into DNA and becoming DNA damage. This allows replication in cancer cells so they can divide and multiply. With an MTH1 inhibitor, the enzyme is blocked and damaged nucleotides enter DNA, causing damage and kill cancer cells. Normal cells do not need MTH1 as they have regulated metabolism preventing damage of nucleotide building blocks. Finding a general enzymatic activity required only for cancer cells to survive opens up a whole new way of treating cancer,"
To take the treatment concept to towards a clinical application, the scientists have taken a multidisciplinary collaboration strategy with researchers from five Swedish universities. They have produced a potent MTH1 inhibitor that selectively kills cancer cells in the tumours that have been surgically removed from skin cancer patients. Dr Roger Olofsson Bagge is a surgeon at Sahlgrenska University Hospital, and also affiliated with the Sahlgrenska Academy at the University of Gothenburg:
"When we saw that the tumour from one of my melanoma patients who has developed resistance to all the current treatment actually responded very well to the treatment, we were extremely happy. It's rare that you get to experience and witness such a breakthrough," he says.
However, a lot of work remains to be done before it is time for clinical trials, which is likely to take at least one or two years, according to Thomas Helleday. In another article published in the same issue of Nature parts of the Swedish research team, together with collaborators in Austria and the UK present results showing that even previously identified substances that kill cancer cells work by inhibiting the MTH1 enzyme, something which has not been realised until now.
"That existing anticancer agents hit the MTH1 shows that the concept really works. Now that we understand the mechanism, we can develop very selective inhibitors", says Thomas Helleday.
Explore further: Acidic tumour pH inhibits drug effect
More information: 'MTH1 inhibition kills cancer by preventing sanitation of the dNTP pool', Helge Gad, Tobias Koolmeister, Ann-Sofie Jemth et al., Nature, online 2 April 2014, DOI: 10.1038/nature13181
'Stereospecific targeting of MTH1 by (S)-crizotinib as anticancer strategy', Kilian V. M. Huber, Eidarus Salah, Branka Radic et al., Nature, online 2 April 2014, DOI: 10.1038/nature13194
Medical Xpress on facebook
Related Stories
Acidic tumour pH inhibits drug effect
Feb 11, 2014
Low pH in tumours counteracts the desired effect of the drug chloroquine, according to a new study from Karolinska Institutet in Sweden. The results, which are published in the journal Autophagy, might explain ...
Novel cancer cell DNA damage repair mechanism unveils
Dec 10, 2013
Research with a Finnish background facilitates the development of more effective cancer medication
New drug candidate starves dormant cancer cells
Feb 18, 2014
In a study published in Nature Communications, researchers at Karolinska Institutet and Uppsala University in Sweden present a new drug candidate, which selectively kills dormant cells within a cancer tumour through starva ...
Alcohol-breakdown molecule may play a role in breast cancer development
Feb 11, 2014
(Medical Xpress)—New research looking at the biological process involved in breast cancer development has strengthened the argument for a potential link between alcohol consumption and the disease.
Cancer vaccine a step closer as natural killer cells are rightly activated
Mar 25, 2014
Vaccines work. Their widespread use has saved millions of lives. With an ageing population that is increasingly becoming a victim to cancer, a vaccine to treat it would do wonders. In a study published in ...
Recommended for you
Pathological complete response predictor of favorable breast cancer outcome
1 hour ago
Results of EORTC trial 10994 appearing in the Annals of Oncology show that pathological complete response after neoadjuvant chemotherapy is an independent predictive factor of favorable clinical outcomes in all ...
An easier, safer, and more accurate treatment for pancreatic cancer
3 hours ago
Using CT scans with contrast enhancement, Dartmouth researchers measured treatment response to pancreatic cancer photodynamic therapy (PDT) according to a paper published in Physics in Medicine and Biology.
Green light for Phase II clinical trial using interstitial photodynamic therapy
4 hours ago
Roswell Park Cancer Institute (RPCI) has received U.S. Food and Drug Administration (FDA) approval to enroll patients in a phase II clinical trial that will use a unique and highly precise method of delivering interstitial ...
Three DNA methylation markers ID recurrence in bladder cancer
5 hours ago
(HealthDay)—For patients with noninvasive urothelial carcinoma, three DNA methylation markers are able to accurately predict tumor recurrence, according to a study published in the April 1 issue of Clinical Ca ...
World-first clinical trial launches for advanced bowel cancer
5 hours ago
Patients with advanced bowel cancer are set to benefit from the launch of a revolutionary new clinical trial targeting treatments to their specific cancer type as well as rapidly adapting to include new drugs ...
Cell metabolism discovery could lead to treatments for cancer, common cold
6 hours ago
(Medical Xpress)—Scientists at UCLA's Jonsson Comprehensive Cancer Center have published the first study explaining in detail how viruses reprogram the metabolism of the cells they invade to promote continued viral growth ...
User comments
© Medical Xpress 2011-2014, Science X network
0 comments:
Post a Comment